Which market first, in what sequence, at what price. Approval, HTA, and reference-pricing interdependence all feed that one call, where the price accepted in one market cascades into the next. Vantro reads them together across 90 markets, cited to source, and hands you the decision, not another report.
Regulatory says approvable. Market access says reimbursable. Commercial says there is a market. Each lens is right on its own, and the launch decision sits across all of them, where clear ownership rarely sits cleanly in one place. So it happens by drift rather than by design.
Vantro exists for that step. It reads the dimensions together and resolves them into one decision: launch or not, which market first, in what sequence, at what price. Every input cited, every estimate marked as an estimate.
For a therapeutic, sequence is a pricing decision before it is a commercial one. Every figure in a brief is cited to source, and every estimate is marked as an estimate.
Reference-pricing systems mean the price you accept in one market cascades into the basket that others price against. Launching in a low-price reference market first can quietly cap your ceiling everywhere downstream.
A regulatory approval is not market access. HTA timelines, evidence requirements, and formulary review run on their own schedule, and the gap between approval and reimbursement is where launch value leaks.
The access decision already set for a comparable product, the evidence a payer accepted, the price they anchored to, shapes what your submission has to clear. The precedent is often the real gate, not the science.
From primary-care volume to specialty and rare disease, across the pathways that decide access and price.
High-value therapeutics where pricing, access, and named-patient routes decide the launch, market by market.
Approval pathway, HTA, and formulary access across emerging and established markets.
Reference-product pathways, interchangeability, and the pricing dynamics reshaping biologic access.
Registration, prequalification, and donor and government procurement channels at scale.
Every dimension of entry behaves differently for therapeutics. A tool built for devices mislabels the decision. Here is where it diverges.
Drug and biologic approval, then HTA. Dossier requirements, stringent-regulator reliance, and post-approval commitments each carry their own timeline and evidence bar.Medtech track: classification and conformity, Class I to III, CE, 510(k), PMA.
Formularies, payers, and reference-pricing systems. A listing decision and the price it carries determine whether the therapeutic is commercially viable in a market.Medtech track: procurement offices, tenders, capital budgets, billing codes.
Clinical trials, real-world evidence, and health-economic models. Adoption runs through prescribers, guidelines, and KOLs.Medtech track: clinical performance, usability, procedure-coding crosswalks.
Reference pricing has turned launch sequencing into a pricing decision. The price accepted in one market cascades into others, which changes where to launch first.Medtech track: reference approvals travel and reshape the pathway.
The four questions are how a market entry decision actually gets made. The six dimensions are what each answer rests on, read for a therapeutic, and rated Ready, Moderate, or Complex. No composite score.
The approval route, reliance procedures available, and post-approval commitments, ahead of the separate HTA and access clock.
The published clock to approval and, separately, to reimbursement, in the regulator’s own units, or marked as unpublished.
How the therapeutic is bought, tender, formulary, or public programme, and what listing status is required to be reimbursed.
How price is set and constrained, reference-pricing exposure, and the effect of a first accepted price on the markets that price against it.
The marketing authorisation holder, local agent, or importer the market requires, and whether it must exist before filing.
Import duty, customs treatment, and the free-zone question as it applies to a therapeutic.
Vantro runs on one body of sourced market data across 90 markets. How that data is framed, and what it leads with, differs by whether you are bringing a therapeutic or a device to market.
Run a brief on any market, or bring us the entry decision in front of you and we will scope it.